



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034,  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, [www.natcopharma.co.in](http://www.natcopharma.co.in)

February 18, 2019

Corporate Relationship Department  
M/s. BSE Ltd  
Dalal Street, Fort  
Mumbai 400 001

Manager – Listing  
M/s. National Stock Exchange of India Ltd  
“Exchange Plaza”, Bandra – Kurla Complex  
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Please find enclosed herewith the Investor Presentation for the Quarter and nine months ended December 31, 2018.

Thanking You.

For NATCO Pharma Limited

A handwritten signature in black ink that reads "M. Adinarayana".

M. Adinarayana  
Company Secretary &  
Vice President (Legal & Corp. Affairs)



# INVESTOR PRESENTATION

Q3 FY19, February 2019



# Disclaimer / Important Disclosure



THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY").

The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares.

This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment and business income (vi) cash flow projections etc. (vii) exposure to market as well as other risks.

The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates.

Any opinions expressed in this presentation are subject to change without notice. The presentation should not be construed as legal, tax, investment or other advice. None of the Company or any of its affiliates, advisers or representatives accepts any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. The information contained in this presentation has not been independently verified. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having been authorized by or on behalf of the Company. Further, past performance is not necessarily indicative of future results.

This document is just a Presentation for information purposes and private circulation only and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the equity shares of the Company or any of its subsidiaries. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from.

This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This presentation is confidential and this presentation or any part thereof should not be used or relied upon by any other party or for any other purpose and should not be copied, reproduced, recirculated, redistributed, published in any media, website or otherwise, in any form or manner, in part or as a whole, without the express consent in writing of the Company. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of the aforesaid should inform themselves about and observe any such restrictions.

# Natco Pharma at a Glance



- Vertically integrated pharmaceutical company with presence across geographies - India, US and ROW
- **Strong brand position** in the domestic Oncology and Hepatitis – C ('Hep-C') segments
  - Portfolio of brands catering to various oncology diseases including breast, bone, lung and ovarian cancer
  - Launched the generic version of Gilead's Sovaldi (Sofosbuvir) and its combinations for the treatment of Hep-C in India
- Focused on **complex generics for the US Markets** with niche Para IV and Para III filings
- **Strong focus on R&D** with over 400 employees dedicated to R&D <sup>(3)</sup>
- Expanding into Niche Agrichemical business, leveraging on its Chemistry and manufacturing skills
- Total revenues<sup>(1)</sup> of INR 22,424 mn for the financial year ended 31<sup>st</sup> March 2018
- Listed on the BSE and NSE with a market capitalization <sup>(2)</sup> of **USD2.14bn**
- Incorporated in 1981 and headquartered in Hyderabad with over 4,830 employees across all locations <sup>(3)</sup>


(1) Represents consolidated revenue from operations (gross)

(2) Market capitalization as of 31<sup>st</sup> March 2018, USD equivalent of ₹5,914


# Track Record of Consistent Growth




## Strong Revenue<sup>(1)</sup> Growth...



## ...And Robust EBITDA and PAT<sup>(2)</sup> Margins



## Ownership Structure<sup>(3)</sup>



## Natco Pharma's Stock Performance over the past 4 and half years<sup>(3)</sup>











FY2014 and FY2015 numbers have been prepared under IGAAP, whereas FY2016, FY2017 and FY2018 numbers have been prepared under Ind AS  
 (1) Represents consolidated gross revenue and includes other income  
 (2) Represents PAT after minority interest

(3) Source: BSE, as of December 31 2018

# Key Business Segments



	Formulations		API (Domestic & Exports)	Others
	Domestic	International		
Overview	<ul style="list-style-type: none"> <li>Strong brand position in the domestic oncology and Hepatitis-C segments</li> <li>Recent foray into the Cardiology and Diabetology segments</li> <li>Specialist sales force of over 350 personnel and over 400 distributors</li> <li>Fall in FY18 revenue due to decline in HepC market size.</li> <li>Expect growth with target launch of 8-10 molecules per year</li> </ul>	<ul style="list-style-type: none"> <li>Focused on complex generics for the US</li> <li>Front end partnerships with leading global generic pharma companies</li> <li>Niche Para IV and Para III filings</li> <li>Emerging presence in Asia, Europe and developing markets</li> </ul>	<ul style="list-style-type: none"> <li>Strategically important division</li> <li>Vertical integration for its Finished Dosage Formulation ('FDF') portfolio</li> <li>Filed 42 DMFs in the US with niche products under development</li> <li>Exports focused on Europe and emerging markets</li> </ul>	<ul style="list-style-type: none"> <li>Operations in Brazil, Canada, Singapore and Australia</li> <li>Selective contract manufacturing business and other operating income</li> </ul>
FY18 Revenue (INRmn)	7,202*	10,418	2,854	1,950
FY18 Revenue Contribution				
Growth FY18 over FY17				

Note: All numbers are Gross Revenue  
All data as of March 31, 2018

\* Includes third party sales

# US Market - Focus on Complex Generics



US FDF product portfolio is predominantly focused on high-barrier-to-entry products that are typically characterised by one or more of the following:

- Intricate chemistry
- Challenging delivery mechanism
- Difficult or complex manufacturing process
- May face complex legal and regulatory challenges

## Key Products in Pipeline

To Be Launched	Key Brand	Molecule	Therapeutic Segment / Indication	Para IV
	Gilenya	Fingolimod	Multiple Sclerosis	✓
	Treanda	Bendamustine	Cancer, CLL	✓
	Nexavar	Sorafenib	Liver, Kidney Cancer	✓
	Tracleer	Bosentan	Hypertension	Para III
	Revlimid(1)	Lenalidomide	Multiple Myeloma	✓
	Afinitor	Everolimus (higher strength)	Kidney Cancer	✓
	Zytiga	Abiraterone	Prostate Cancer	✓
	Tarceva	Erlotinib	NSCLC, Pancreatic Cancer	✓
	Kyprolis	Carfilzomib	Multiple Myeloma	✓
	Aubagio	Teriflunomide	Multiple Sclerosis	✓
	Eliquis	Apixaban	Anticoagulant	✓
	Pomalyst	Pomalidomide	Multiple Myeloma	✓
Sovaldi	Sofosbuvir	Anti-Viral / Hep C	✓	
Ibruvika	Ibrutinib	Cancer	✓	

## Low Risk Business Model through Partnerships with Global Pharmaceutical Players

- Adopted and successfully implemented partnership strategy for international formulation products
  - Has product specific partnerships with global generic players at different stages of a potential ANDA filing
  - Low risk business model:
    - Marketing partner typically responsible for the litigation and regulatory process to secure the ANDA approval
    - Multi-site approvals
    - Multi-sourcing arrangements
  - Profit sharing arrangements with the front end partners.

- Pipeline of niche and complex generics products in US
- 29 approved ANDAs<sup>(2)</sup>
- 16 Para IVs yet to be launched <sup>(2)</sup>

(1) Launch conditional on approval


(2) As of March 31, 2018. Approval received either by Natco or its marketing partner

# Strong Growth in Domestic Formulations Business



## Domestic Formulation Sales<sup>(1)</sup>: Market Leading Growth

INRmn



## Domestic Product Launches

In FY 17-18, Natco had the following product launches

- In the Oncology segment – Alphalan, Carfilnat and Pomalid
- In the Speciality Pharma segment – Tafnat and Velpanat
- In the Cardiology segment – Arganat and Dabigat

Brand	Molecule	Dosage Form	Therapeutic Segment
Denopsy	Teriflunomide	Tablets	Speciality Pharma
Posanat	Posaconazole	Injection	Speciality Pharma
Herduo	Lapatinib	Tablets	Oncology
Hepcinat Plus	Sofosbuvir+ Daclatasvir	Tablets	Speciality Pharma

FY19 – UPTO Q3

## Strong position in Oncology and Hepatitis-C domains

6

Brands in excess of INR 100mn+ sales in Oncology segment

4

Brands occupy the #1 position in Hep-C segment

350+

Sales force in India across Oncology, Gastro Hepatology, Cardiology and Diabetology

FY2014 and FY2015 numbers have been prepared under IGAAP, whereas FY2016, FY2017 and FY2018 numbers have been prepared under Ind AS

(1) Represents gross revenue  
\* Includes third party sales



# Strong Market Position in Domestic Oncology Segment



## Oncology Division Overview

- Entered the segment with launch of generic version of Imatinib in 2003
- Portfolio of well recognized brands – 6 brands with INR 100mn+ sales in the oncology segment
- Progressively widened its oncology product range from **6** in 2003-04 to **30<sup>(1)</sup>**
- Sales and marketing of the product is supported by approximately 70 sales representatives and strategically located logistics network of distributors

## Oncology Portfolio

Hematology


Solid Tumors

# of Active Brands<sup>(1)</sup>

13

17

## Oncology Revenue – Gross (INRmn)



## INR100mn+ Brands (FY18)<sup>(2)</sup>



## Gastro Hepatology – Leading Market Position in Hep-C Portfolio

- Launched generic Sofosbuvir and its combinations for the treatment of Hep-C in India & Nepal under its brand **Hepcinat & Hepcinat LP**
- Non-exclusive licensing agreement with Gilead Sciences for 105 countries including India
- Launched generic Daclatasvir in India under its brand **Natdac** and an oral fixed-dose combination of Sofosbuvir and Velapatasvir under its brand **Velpanat**
- Market leading positions across the Hep-C class of drugs in India
- Sales and marketing of the product is supported by approximately 120 sales representatives

## Extending the Hep-C Franchise


- Launched **Hepcinat Plus**, a generic fixed dose combination of Sofosbuvir and Daclatasvir for the first time in India
- Foraying into RoW markets

## Emerging portfolio of Hep B

- Launched Tenofovir Alafenamide tablets under its brand **Tafnat** as an extension to existing Hep B portfolio of Tenofovir (Teravir) & Entecavir (X-Vir) tablets

## Expanding Into Emerging Markets Of Asia And Africa

- Import Permits & Approvals Received
- Access via Agreement with Gilead



Import permits / approvals for Hep-C related drug received in 14 countries<sup>(1)</sup>


(1) Including India

# Expanding Domestic Presence with CnD Division



## Cardiology and Diabetology


- Launched Cardiology and Diabetology (CnD) division in early 2017
- First to launch Argatroban injection and Dabigatran in India for treatment of patients with thrombosis syndrome
- Focus will be on niche molecules with high barriers to entry



# Expanding RoW Presence



## Focus on Canada, Brazil and other RoW markets



### Hep-C driven markets

- Received approvals and import permits for 14 countries<sup>(1)</sup>

### Europe

- Distribution arrangements with our business partner to sell our products in Eastern Europe, UK and Germany

# In-House API Development with Vertical Integration for Key Formulation Products



- Strategically important business – develops APIs primarily for captive consumption of its FDF portfolio as well as third party sales
- Portfolio of 42 US DMFs<sup>(1)</sup> with with niche products under development
- Focuses on complex molecules in oncology and CNS segments
  - Other therapeutic areas of focus includes Anti-asthmatic, Anti-depressant, Anti-migraine, Anti-osteoporosis and G I Disorders
- Exports are focused on the US, EU, Canada, Latin America and South-East Asia
- Vertical integration for several APIs a key competitive advantage

## API Strengths

- Complex multi-step synthesis & scale-up
- Semi-synthetic fusion technologies
  - Fermentation / Biotech / Synthetic / Separation technologies
- Containment / High potency APIs
- Peptide (Solid phase) pharmaceuticals

	Mekaguda Facility	Chennai Facility
<b>Chemistry Skills</b>	<ul style="list-style-type: none"> <li>Complex chemistry peptides</li> </ul>	<ul style="list-style-type: none"> <li>Cytotoxic API's and Biotechnology based products</li> <li>Synthetic chemistry</li> </ul>
<b>Key Regulatory Approvals</b>	<ul style="list-style-type: none"> <li>GMP, USFDA, German Health Authority, PMDA (Japan), Cofepris (Mexico)</li> </ul>	<ul style="list-style-type: none"> <li>GMP, USFDA</li> </ul>
<b>Last US FDA Audit</b>	<ul style="list-style-type: none"> <li>US FDA audit with Zero observations completed in February 2018</li> </ul>	<ul style="list-style-type: none"> <li>US FDA audit – EIR Received August 2016</li> </ul>

Expansion plans to augment API manufacturing capacity

(1) As of March 31, 2018


# Research & Development Capabilities




## R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments

- Two research facilities with capabilities across synthetic chemistry, biotech & fermentation, nano pharmaceuticals, new drug discovery & cell biology

### R&D Expense (INRmn) and as % of Standalone Revenue



### Talented Pool of Scientists (Total no: 271)<sup>(1)</sup>



Note: Rounded off to the nearest decimal

Note: Rounded off to the nearest decimal

### Over 35 R&D laboratories in 2 research facilities

29 ANDAs Approved<sup>(2)</sup>

16 Para IVs to be Launched<sup>(2)</sup>

42 US DMFs Filed<sup>(2)</sup>



Several International and Indian patents filed and granted

FY2014 and FY2015 numbers have been prepared under IGAAP, whereas FY2016 and FY2017 numbers have been prepared under Ind AS



(1) As of March 31, 2018.

(2) As of March 31, 2018. Approval received either by Natco or its marketing partner





# Commitment to Manufacturing Excellence with a Culture of Quality and Compliance



## International Markets Formulations

	Kothur Facility	Visakhapatnam Facility
		
<b>Capability</b>	<ul style="list-style-type: none"> <li>Tablets, Capsules, Pellets, Injectables</li> </ul>	<ul style="list-style-type: none"> <li>Cytotoxic &amp; other Oral Solid Dosages</li> </ul>
<b>Key Regulatory Approvals</b>	<ul style="list-style-type: none"> <li>GMP, USFDA, German Health Authority, ANVISA</li> </ul>	<ul style="list-style-type: none"> <li>na</li> </ul>
<b>Other Highlights</b>	<ul style="list-style-type: none"> <li>US FDA audit – EIR Received July 2017</li> </ul>	<ul style="list-style-type: none"> <li>Targeted towards US &amp; other International regulated markets</li> <li>Located in a Special Economic Zone (SEZ)</li> <li>Facility license received. Qualification batches in progress</li> </ul>

## Domestic Market Formulations

	Nagarjuna Sagar Facility	Dehradun Unit 6 Facility	Dehradun Unit 7 Facility	Guwahati Facility
				
<b>Capability</b>	<ul style="list-style-type: none"> <li>Ampoules, Vials, Lyophilized vials, Parenterals, Sterile Dry Powders</li> </ul>	<ul style="list-style-type: none"> <li>Tablets, Capsules, Injectables</li> </ul>	<ul style="list-style-type: none"> <li>Tablets, Capsules</li> </ul>	<ul style="list-style-type: none"> <li>Tablets, Capsules</li> </ul>
<b>Key Regulatory Approvals</b>	<ul style="list-style-type: none"> <li>GMP</li> </ul>	<ul style="list-style-type: none"> <li>GMP</li> </ul>	<ul style="list-style-type: none"> <li>GMP, Public Health Service of the Netherlands (EU GMP)</li> </ul>	<ul style="list-style-type: none"> <li>GMP Compliant Facility</li> </ul>

 Under development

# Experienced Management



**Mr. V.C Nannapaneni**  
*Chairman and Managing Director*

- Holds Masters degree in Pharmaceutical Administration from the Long Island University, USA
- Over 4 decades of experience in the pharmaceutical industry



**Mr. Rajeev Nannapaneni**  
*Vice Chairman & CEO*

- Holds bachelors degree in Quantitative Economics and History from Tufts University, Boston, USA
- Has 15 years of experience in the pharmaceutical industry



**Mr. P.S.R.K Prasad**  
*Executive Vice President (Corp. Engineering Services)*

- Holds B.E. Mech. Engg. from Andhra University, Visakhapatnam
- Responsible for looking after the general administration, engineering, regulatory, training, environmental matters, safety, health, production and maintenance activities of the Company



**Dr. Linga Rao**  
*President (Technical Affairs)*

- Holds Masters degree in Science (Applied Chemistry) & Ph.D in Chemistry from JNTU, Hyderabad
- Over 4 decades of experience in the pharmaceutical industry and has been working with Natco for over 23 years



**M. Adinarayana**  
*Company Secretary & VP-Legal & Corporate Affairs*

- Bachelors in Commerce and Bachelors in Law from Andhra University, Fellow Member of Institute of Company Secretaries of India
- 24+ years of experience within the Company in legal, secretarial and patent litigation areas



**Mr. S.V.V.N.Appa Rao**  
*CFO*

- Over 27 years of experience including 22 years within the Company covering areas of accounting, financial controller, treasury
- Responsible for finance and treasury functions at the Company



**Dr. Pulla Reddy M**  
*Executive Vice President - R&D*

- Holds Masters in Science (Chemistry) and Ph.D in Chemistry, both from University of Hyderabad. Did postdoctoral research for 2.5 years at University of Zurich, Switzerland
- 24 years experience at Natco with key role in developing novel commercially viable processes for over 100 APIs and intermediates



**Dr. Rami Reddy B**  
*Director - Formulations*

- Holds M. Pharm and Ph.D. (Pharmaceutics) degree from Nagpur University
- 32 years of experience in the Pharmaceutical Formulation industry. Responsible for Formulation plant operations, Product development and Regulatory compliance



**Mr. Rajesh Chebiyam**  
*Vice President - Acquisitions, Institutional Investor Mgmt. & Corporate Communications*

- Holds MBA from Babson College (USA) and Masters degree in Chemical Engineering from University of Rhode Island
- 20+ years of experience across supply chain, operations, business development, sales and strategy



# Natco's Near and Long-Term Goals



## Domestic Branded Formulations

## Complex Generics & Export Markets

### Near-term Strategies

- Maintain leadership position in Oncology and Hepatitis-C segment
- Intensify the focus of CnD pipeline for niche launches
- Launch 8-10 new products
- Entered niche agrichemical business

- Focus on growth in key subsidiaries of Canada & Brazil
- Intensify regulatory filings rate in RoW markets led by Hep-C portfolio

### Long-term Strategies

- Enter new attractive segments
- Growth through inorganic strategies


- Focus on a select few high-potential filings, predominantly differentiated products through either Novel Drug Delivery Systems (NDDS) or complex chemistries
- Strategic alliances in RoW markets for further growth

# Demonstrated Track Record of Topline and Earnings Growth




FY2014 and FY2015 numbers have been prepared under IGAAP, whereas FY2016 and FY2017 numbers have been prepared under Ind AS


### Total Gross Revenue<sup>(1)</sup> (INRmn)




### EBITDA (INRmn) and EBITDA Margin (%)




### PAT<sup>(2)</sup> (INRmn) and PAT Margin (%)



### ROE (%)



### ROCE (%)



(1) Represents consolidated gross revenue and includes other income  
 (2) Represents PAT after minority interest

# Historical Financials



## Consolidated Profit & Loss Statement (INRmn)

Particulars	31-March-2018	31-March-2017
<b>Revenue</b>		
Revenue from operations (Refer note 5)	22,020	20,650
Other income	404	139
<b>Total revenues</b>	<b>22,424</b>	<b>20,789</b>
<b>Expenses</b>		
Cost of materials consumed	3,905	5,208
Excise duty (Refer note 5)	172	448
Purchases of stock-in-trade	459	971
Changes in inventories of finished goods, stock-in-trade and work-in-progress	(253)	(188)
Employee benefits expense	3,256	2,432
Finance costs	154	185
Depreciation and amortisation expense	662	544
Other expenses	5,197	4,945
<b>Total expenses</b>	<b>13,552</b>	<b>14,545</b>
<b>Profit before tax</b>	<b>8,872</b>	<b>6,244</b>
<b>Tax expense / (credit)</b>		
Current tax	2,199	1,354
Deferred tax	-	1
Minimum alternative tax credit	(279)	-
Tax for earlier years	-	40
<b>Profit after tax</b>	<b>6,952</b>	<b>4,849</b>
<b>Other comprehensive income (net of taxes)</b>		
<b>Items that will not be reclassified to profit or loss</b>		
Re-measurement gains/(losses) on defined benefit plans	(42)	(50)
Net (loss)/gain on FVTOCI equity securities	(2)	28
<b>Items that will be reclassified to profit or loss</b>		
Exchange differences on translation of foreign operations	(8)	(12)
<b>Total comprehensive income</b>	<b>6,900</b>	<b>4,815</b>
<b>Profit attributable to:</b>		
Owners of the parent	6,962	4,860
Non-controlling interests	(10)	(11)
<b>Total comprehensive income attributable to:</b>		
Owners of the parent	6,910	4,826
Non-controlling interests	(10)	(11)
<b>Paid-up equity share capital of ₹each</b>	<b>369</b>	<b>349</b>
<b>Other equity (Revaluation reserve ₹Nil)</b>	<b>30,353</b>	<b>16,144</b>
<b>Earnings per share (non-annualised)</b>		
Basic (in ₹)	39.26	27.78
Diluted (in ₹)	39.13	27.75

## Consolidated Balance Sheet (INRmn)

Particulars	31-March-2018	31-March-2017
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	10,127	8,272
(b) Capital work-in-progress	4,800	3,363
(c) Intangible assets	59	58
(d) Financial assets		
Investments	81	1
Other financial assets	150	131
(e) Current-tax assets (net)	18	-
(f) Other non-current assets	609	478
	<b>15,844</b>	<b>12,303</b>
<b>Current assets</b>		
(a) Inventories	4,384	3,489
(b) Financial Assets		
Investments	684	321
Trade receivables	6,375	4,752
Cash and cash equivalents	217	235
Bank balances other than cash and cash equivalents	1,620	123
Loans	45	35
Other financial assets	6,142	752
(c) Other current assets	1,840	1,166
	<b>21,307</b>	<b>10,873</b>
<b>Total assets</b>	<b>37,151</b>	<b>23,176</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	369	349
(b) Other equity	30,353	16,144
<b>Equity attributable to owners</b>	<b>30,722</b>	<b>16,493</b>
Non-controlling interest	38	41
<b>Total of Equity</b>	<b>30,760</b>	<b>16,534</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Other financial liabilities	8	8
(b) Provision for employee benefits	324	219
(c) Deferred tax liabilities (net)	139	150
	<b>471</b>	<b>377</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	1,732	2,216
Trade payables	2,691	2,627
Other financial liabilities	1,024	1,014
(b) Other current liabilities	310	257
(c) Provision for employee benefits	137	18
(d) Current-tax liabilities (net)	26	133
	<b>5,920</b>	<b>6,265</b>
<b>Total equity and liabilities</b>	<b>37,151</b>	<b>23,176</b>

# Historical Financials (contd.)



Segmental Breakdown (INR Mn)				
Revenue Division	Q3FY19	FY18	Q3FY18	FY17
Total API				
<b>API Gross Revenue</b>	<b>992.5</b>	<b>2,853.9</b>	<b>816.6</b>	<b>1,837.7</b>
Formulation export and profit share	2,573.1	10,419.0	2,890.3	8276.0
Formulations Onco (including CnD)	942.5	3,380.6	848.3	3,224.3
Formulations, Brand Pharma Non - Onco	503.2	3,103.5	685.6	4,801.6
Formulations, 3rd party, & miscel	195.6	718.2	125.7	784.6
<b>Formulations Gross Revenue</b>	<b>4,214.4</b>	<b>17,620.9</b>	<b>4,549.9</b>	<b>17,086.1</b>
Other Operating and Non - operating incomes	349.1	1,003.9	148.5	1,236.0
<b>Stand-Alone Total Net Revenue</b>	<b>5,556.0</b>	<b>21,479</b>	<b>5,515.0</b>	<b>20,159.8</b>
Total Revenue, all subsidiaries	244.0	945.3	221.0	630.0
<b>Consolidated Total Net Revenue</b>	<b>5,800.0</b>	<b>22,424.0</b>	<b>5,736.0</b>	<b>20789.8</b>

Consolidated Financial Results (INR Mn)				
	Q3FY19	FY18	Q3 FY18	FY17
<b>Total Revenues</b>	<b>5,800</b>	<b>22,424</b>	<b>5736</b>	<b>20,789</b>
<b>EBITDA</b>	<b>2317</b>	<b>9,688</b>	<b>2979</b>	<b>6,973</b>
EBITDA Margin (%)	39.9%	43.20%	51.9%	33.50%
<b>PAT (after minority interest)</b>	<b>1593</b>	<b>6,962</b>	<b>2174</b>	<b>4,860</b>
PAT Margin (%)	27.5%	31.00%	37.9%	23.40%